The Therapeutics of Intermittent Fever PDF Download

Author: Henry C. Allen
Publisher:
ISBN:
Category : Fever
Languages : en
Pages : 354

View

Book Description

Author: Henry Clay Allen
Publisher:
ISBN:
Category :
Languages : en
Pages : 382

View

Book Description

Author: William Austin Allen
Publisher:
ISBN:
Category : Homeopathy
Languages : en
Pages : 122

View

Book Description

Author: Henry C. Allen
Publisher:
ISBN:
Category : Homeopathy
Languages : en
Pages : 272

View

Book Description

Author: H. C. Allen
Publisher: B. Jain Publishers
ISBN: 9788170213000
Category : Health & Fitness
Languages : en
Pages : 348

View

Book Description
The difficulty of mastering our voluminous and rapidly increasing symptomatology, has naturally led to the demand for monographs and repertories; hence to the bracketed comparison have been added some leading characterstics of each remedy & repertory.

Author: H. C. Allen
Publisher: B. Jain Publishers
ISBN: 9788170210818
Category : Health & Fitness
Languages : en
Pages : 580

View

Book Description
Fever is so often suppressed in North America that characterization and differentiation of fevers seems a lost art. It is a Materia Medica which is useful in the treatment of fevers. Characteristics and differentials are mentioned. A repertory is appended which is very useful.

Author: Samuel Lilienthal
Publisher:
ISBN:
Category : Homeopathy
Languages : en
Pages : 864

View

Book Description

Author: Wells
Publisher: B. Jain Publishers
ISBN: 9788180563140
Category : Health & Fitness
Languages : en
Pages : 268

View

Book Description
The Falsehood Of The Oft-Repeated Homoeopathy Will Not Cure Ague Has Been Demonstrated In The Book And The Author Assure Us That There Is No More Diffuculty In Treating Intermittent Fever That In Treating Any Other Disease.

Author: Ann Arvin
Publisher: Cambridge University Press
ISBN: 1139461648
Category : Medical
Languages : en
Pages : 1325

View

Book Description
This comprehensive account of the human herpesviruses provides an encyclopedic overview of their basic virology and clinical manifestations. This group of viruses includes human simplex type 1 and 2, Epstein–Barr virus, Kaposi's Sarcoma-associated herpesvirus, cytomegalovirus, HHV6A, 6B and 7, and varicella-zoster virus. The viral diseases and cancers they cause are significant and often recurrent. Their prevalence in the developed world accounts for a major burden of disease, and as a result there is a great deal of research into the pathophysiology of infection and immunobiology. Another important area covered within this volume concerns antiviral therapy and the development of vaccines. All these aspects are covered in depth, both scientifically and in terms of clinical guidelines for patient care. The text is illustrated generously throughout and is fully referenced to the latest research and developments.

Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309459575
Category : Medical
Languages : en
Pages : 483

View

Book Description
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.